GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Finch Therapeutics Group Inc (OTCPK:FNCH) » Definitions » FCF Yield %

FNCH (Finch Therapeutics Group) FCF Yield % : -95.79 (As of Dec. 12, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Finch Therapeutics Group FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Finch Therapeutics Group's Trailing 12-Month Free Cash Flow is $-18.06 Mil, and Market Cap is $18.85 Mil. Therefore, Finch Therapeutics Group's FCF Yield % for today is -95.79%.

The historical rank and industry rank for Finch Therapeutics Group's FCF Yield % or its related term are showing as below:

FNCH' s FCF Yield % Range Over the Past 10 Years
Min: -2029.49   Med: -168.72   Max: -3.47
Current: -95.79


During the past 5 years, the highest FCF Yield % of Finch Therapeutics Group was -3.47%. The lowest was -2029.49%. And the median was -168.72%.

FNCH's FCF Yield % is ranked worse than
84.14% of 1507 companies
in the Biotechnology industry
Industry Median: -12.65 vs FNCH: -95.79

Finch Therapeutics Group's FCF Margin % for the quarter that ended in Jun. 2024 was 0.00%.


Finch Therapeutics Group FCF Yield % Historical Data

The historical data trend for Finch Therapeutics Group's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Finch Therapeutics Group FCF Yield % Chart

Finch Therapeutics Group Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
FCF Yield %
- - -17.55 -333.97 -543.49

Finch Therapeutics Group Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -267.58 -253.11 -255.73 -417.90 -859.32

Competitive Comparison of Finch Therapeutics Group's FCF Yield %

For the Biotechnology subindustry, Finch Therapeutics Group's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Finch Therapeutics Group's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Finch Therapeutics Group's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Finch Therapeutics Group's FCF Yield % falls into.



Finch Therapeutics Group FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Finch Therapeutics Group's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-31.505 / 5.7967936
=-543.49%

Finch Therapeutics Group's annualized FCF Yield % for the quarter that ended in Jun. 2024 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-4.726 * 4 / 2.1998912
=-859.32%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Finch Therapeutics Group FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Finch Therapeutics Group FCF Yield % Related Terms

Thank you for viewing the detailed overview of Finch Therapeutics Group's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Finch Therapeutics Group Business Description

Traded in Other Exchanges
N/A
Address
75 State Street, Suite 100, Boston, MA, USA, 02109
Finch Therapeutics Group Inc is a microbiome technology company with a portfolio of intellectual property and microbiome assets. Finch has a robust intellectual property estate reflecting the company's pioneering role in the microbiome therapeutics field, including more than 70 issued U.S. and foreign patents with critical relevance for both donor-derived and donor-independent microbiome therapeutics in a range of potential indications. The company's assets include CP101, an investigational, orally administered microbiome candidate with positive clinical date from a Phase 2 randomized, placebo-controlled trial and a Phase 2 open-label trial in recurrent C. difficile infection (CDI).
Executives
Jeffery A Smisek director 1600 SMITH STREET, HQSEO, HOUSTON TX 77002
Susan E Graf director 400 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Lance E Thibault officer: Chief Financial Officer
Matthew P. Blischak officer: Chief Executive Officer C/O FINCH THERAPEUTICS GROUP, INC., 200 INNER BELT ROAD, SOMERVILLE MA 02143
Joseph Vittiglio officer: Chief Business & Legal Officer C/O BLUEBIRD BIO, INC., 455 GRAND UNION BLVD, SOMERVILLE MA 02145
Marc Blaustein officer: Chief Operating Officer C/O FINCH THERAPEUTICS GROUP, INC., 200 INNER BELT ROAD, SUITE 400, SOMERVILLE MA 02143
Domenic J Ferrante director BROOKSIDE CAPITAL MANAGEMENT LLC, JOHN HANCOCK TOWER, 200 CLARENDON STREET, BOSTON MA 02116
Samuel A Hamood director C/O TRANSUNION, 555 WEST ADAMS STREET, CHICAGO IL 60661
Joanne L. Viney director C/O HARPOON THERAPEUTICS, INC., 131 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Nicholas Haft director C/O FINCH THERAPEUTICS GROUP, INC., 200 INNER BELT ROAD, SUITE 400, SOMERVILLE MA 02143
Christian H. Lange director 28 HAVEMEYER PLACE, GREENWICH CT 06830
Crestovo Investor Llc director, 10 percent owner 28 HAVEMEYER PLACE, GREENWICH CT 06830
Gregory D Perry officer: Chief Financial Officer C/O IMMUNOGEN, INC., 830 WINTER ST., WALTHAM MA 02451
Chris Shumway director, 10 percent owner 28 HAVEMEYER PLACE, GREENWICH CT 06830
Zain Kassam officer: Chief Medical Officer C/O FINCH THERAPEUTICS GROUP, INC., 200 INNER BELT ROAD, SUITE 400, SOMERVILLE MA 02143